Reviewing Telomir Pharmaceuticals (TELO) & Its Competitors

Telomir Pharmaceuticals (NASDAQ:TELO) is one of 1,069 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Telomir Pharmaceuticals to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends.

Earnings and Valuation

This table compares Telomir Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	-$16.53 million	-7.86
Telomir Pharmaceuticals Competitors	$9.94 billion	$137.22 million	-7.93

Telomir Pharmaceuticals’ rivals have higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Telomir Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-1,170.58%	-832.67%
Telomir Pharmaceuticals Competitors	-3,399.87%	-235.11%	-32.77%

Analyst Ratings

This is a summary of current ratings and price targets for Telomir Pharmaceuticals and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	0	0	1	1	3.50
Telomir Pharmaceuticals Competitors	8315	22100	50179	1341	2.54

Telomir Pharmaceuticals presently has a consensus target price of $15.00, indicating a potential upside of 228.95%. As a group, “Pharmaceutical preparations” companies have a potential upside of 206.13%. Given Telomir Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Telomir Pharmaceuticals is more favorable than its rivals.

Summary

Telomir Pharmaceuticals rivals beat Telomir Pharmaceuticals on 7 of the 12 factors compared.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.